A new CT-based online calculator predicts survival benefits from adjuvant transarterial chemoembolization after surgical resection in hepatocellular carcinoma patients.

• 35.4% of patients evaluated may benefit from pa-tace, increasing 5-year overall survival probability by 19.4% and adding 22.5 months of restricted mean survival time.
• The tool outperforms traditional staging systems with a c-index of 0.694 and an integrated Brier score ≤ 0.176.

Surgeons can use this online resource to tailor postoperative protocols and address high-risk patients effectively.

A study comparing Warshaw vs. Kimura techniques for spleen-preserving distal pancreatectomy shows crucial differences in outcomes.

• Warshaw is preferred for larger tumors (2.5 cm vs. 1.5 cm) and complex cases, while Kimura offers shorter operative times and is more often minimally invasive (73.1% vs. 44.1%).
• Long-term complications like splenic hypoperfusion are more frequent after Warshaw (30.4% vs. 12.2%), though mostly asymptomatic.

Surgeons should choose technique based on tumor characteristics to minimize complications and optimize patient recovery.

• Need for secondary splenectomy is rare at only 1.2%.

Integrating surgery with chemotherapy may extend survival for some patients with stage IV pancreatic cancer and liver metastases.

• Patients undergoing combined surgery and chemotherapy had a median overall survival of 18 months, whereas those on chemotherapy alone showed significantly less.
• Younger patients (under 65) had a reduced mortality risk (HR = 1.3), and tumor location was a key survival predictor; those with tumors in the body (HR = 0.5) or tail (HR = 0.4) had lower mortality risks than those with head tumors.

Careful patient selection is crucial, as the observed survival benefit may reflect these factors rather than a direct treatment effect.